Next Article in Journal
Sea Ice Microorganisms: Environmental Constraints and Extracellular Responses
Next Article in Special Issue
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
Previous Article in Journal
Dynamic Interplay of Smooth Muscle α-Actin Gene-Regulatory Proteins Reflects the Biological Complexity of Myofibroblast Differentiation
Article Menu

Export Article

Open AccessReview
Biology 2013, 2(2), 587-602;

Antitumor Virotherapy by Attenuated Measles Virus (MV)

INSERM, UMR892, Nantes, F-44000, France
CNRS, UMR6299, Nantes, F-44000, France
Université de Nantes, Nantes, F-44000, France
CNRS, URA3015, Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, 75015, France
Author to whom correspondence should be addressed.
Received: 4 February 2013 / Revised: 28 February 2013 / Accepted: 5 March 2013 / Published: 28 March 2013
(This article belongs to the Special Issue RNA Viruses and Cancer)
Full-Text   |   PDF [174 KB, uploaded 28 March 2013]


Antitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor into cells. This molecule negatively regulates the complement system and is frequently overexpressed by cancer cells to escape lysis by the complement system. MV exhibits oncolytic properties in many cancer types in vitro, and in mouse models. Phase I clinical trials using MV are currently underway. Here, we review the state of this therapeutic approach, with a focus on the effects of MV on the antitumor immune response. View Full-Text
Keywords: antitumor virotherapy; measles virus vaccine; dendritic cells; tumor antigen; clinical trial; vaccine antitumor virotherapy; measles virus vaccine; dendritic cells; tumor antigen; clinical trial; vaccine
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Guillerme, J.-B.; Gregoire, M.; Tangy, F.; Fonteneau, J.-F. Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology 2013, 2, 587-602.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biology EISSN 2079-7737 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top